Technivie & Viekira XR: Two Discontinued Hep C Treatments

Two medications for the treatment of hepatitis C, Technivie and Viekira XR, have been discontinued, according to the Food and Drug Administration (FDA). The discontinuation is voluntary and not related to safety, quality, or efficacy of the medications.^1,2 Viekira XR and Technivie are both manufactured by AbbVie.

Both products are estimated to fbe available until January 1, 2019.

What should I know about these medications?

Viekira XR (dasabuvir sodium; ombitasvir; paritaprevir; ritonavir) was approved by the FDA in 2016 for treatment of adults with chronic hepatitis C genotype 1 who have compensated cirrhosis or do not have cirrhosis at all.

Viekira XR is the extended-release formulation of Viekira Pak, which is currently still available.

Technivie was FDA-approved in 2015 for the treatment of chronic hepatitis C genotype 4 who have compensated cirrhosis or do not have cirrhosis at all. Technivie is indicated for use with ribavirin.

What other treatments are available?

The discontinuation of Viekira XR and Technivie will leave two fewer treatment options of chronic hepatitis C; However, there are several other effective treatment options available.

Treatment options for adults with hepatitis C genotype 1 include:

• Daklinza plus Sovaldi
• Epclusa
• Harvoni
• Mavyret
• Olysio plus Sovaldi or peginterferon and ribavirin
• Viekira Pak
• Viekira XR
• Zepatier

Treatment options for adults with hepatitis C genotype 4 include:

• Epclusa
• Harvoni
• Mavyret
• Olysio plus Sovaldi or peginterferon and ribavirin
• Sovaldi plus ribavirin
• Technivie
• Zepatier

It's always important to discuss which treatment is best for you with your doctor or healthcare team.